Description for experts
The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).
Description for laymen
JSON Data
{
"short_title": "PROTECT",
"data_mode": "900",
"data_mode_number": "000002372",
"official_title": "PROton versus photon Therapy for Esophageal Cancer. A Trimodality strategy (PROTECT).\r\n\r\nA multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer.",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "kurativ",
"therapieintervention_value": "neoadjuvant",
"therapielinie_value": null,
"ctgov_number": "050555648",
"eudract_number": null,
"general_contact_email": "str.studien@uniklinikum-dresden.de",
"general_contact_phone": "+49 351-4582238",
"hauptpruefer_dd_name": "Prof. Dr. med. Dr. Esther Troost",
"description_laie_de": null,
"description_laie_en": null,
"description_expert_de": null,
"description_expert_en": "The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).",
"rechtsgrundlage_value": "BO",
"phase_amg_value": null,
"main_cat_id": 2,
"sub_cat_id": 5
}
